Clinical Trials Directory

The Endometrial Cancer Molecularly Targeted Therapy Consortium is a multi-institutional alliance that is developing a cancer data and tissue repository. The information in this repository will be used to better understand tumor alterations and cancer biomarkers that can help us develop new therapies and potentially improve survival outcomes for women with endometrial cancer.

We are doing this study to find out if a new vaccine (ESR1 peptides) is safe and if they will help people with estrogen receptor positive (ER+) breast cancer.

We are doing this study to keep tabs on the performance of a medical device called TVT Exact. This device is used to help control stress urinary incontinence. We want to know how well this device works long-term in Duke patients who elected to use it.

We are doing this study to find out if a drug called fluoxetine (the study drug) can cause changes to structures in your cells called lysosomes that then improve how well the chemotherapy drug temozolomide (TMZ) kills cancer cells in the brain. Lysosomes are organelles (structures in cells) that contain digestive enzymes (substances that break down chemicals) that help keep the cells free of extra or worn out cell parts. The study drug is approved by the FDA to treat problems like depression and anxiety, but we do not know if it also might be beneficial in treating cancer.

We are doing this study to find out if surgically removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing melanoma from coming back in the same area of the lymph node excision. We also want to learn more about the side effects of this type of surgery and how it can impact patients' quality of life.

We are doing this study to learn more about a medical technology called the ExoDx Prostate test. We want to find out if these test results can help us evaluate the risk of prostate cancer for patients and make better informed clinical decisions.

We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.

We are doing this study to find out if the experimental combination of the drugs finalimab and cemiplimab (the study drugs) is a safe and effective option for people with high-risk melanoma. We want to see how well the study drugs work compared to treatment with pembrolizumab.